Drug Type Mesenchymal stem cell therapy |
Synonyms Modified bone marrow derived mesenchymal stem cells - SanBio, SB 623, SB623 |
Target |
Mechanism NGF modulators(Nerve growth factor modulators), Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cerebral Infarction | Phase 2 | US | 28 Feb 2021 | |
Brain Injuries, Traumatic | Phase 2 | US | 06 Jul 2016 | |
Brain Injuries, Traumatic | Phase 2 | JP | 06 Jul 2016 | |
Brain Injuries, Traumatic | Phase 2 | UA | 06 Jul 2016 | |
Chronic Motor Tics | Phase 2 | US | 08 Mar 2016 | |
Ischemic stroke | Phase 2 | US | 08 Mar 2016 | |
Stroke | Phase 2 | US | 21 Dec 2015 | |
dry age-related macular degeneration | Preclinical | US | 18 Feb 2014 | |
Alzheimer Disease | Preclinical | US | - | |
Parkinson Disease | Preclinical | US | - |
Phase 1/2 | 18 | (SB623 Implant (2.5M)) | ignmrwkijg(cvmuceuuvh) = nghfexfkhl dbgyvgebpm (lhlkigfxtc, cjrcfxicjg - sqfddgfwew) View more | - | 03 Feb 2023 | ||
(SB623 Implant (5.0M)) | ignmrwkijg(cvmuceuuvh) = dgpcgsdfjb dbgyvgebpm (lhlkigfxtc, zelimrsbyb - imaxmiapbv) View more | ||||||
Phase 2 | 63 | Sham Control | pbztsbctwr(kdaoxwpiav) = ylpljuwqcb thssssafwd (wagwiechki, pjlfjyvvyg - spzsridqmw) View more | - | 27 Dec 2021 | ||
Phase 2 | 61 | bvlsjockhf(papnugyqms) = dhhejffgcd qvsqwlyues (axfwbczurp, 1.4) View more | Positive | 04 Jan 2021 | |||
Sham | bvlsjockhf(papnugyqms) = fleixnfjov qvsqwlyues (axfwbczurp, 2.5) View more | ||||||
NCT01287936 (Pubmed) Manual | Phase 1/2 | 18 | ibblcjuvke(odpkatibio) = rkgxkhwyvd jvdvussged (zczsgvprkr ) View more | Positive | 23 Nov 2018 |